Research progress on the relationship between hypoglycemic drugs and sarcopenia

doi:10.12092/j.issn.1009-2501.2023.01.013

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (1): 101-108.doi: 10.12092/j.issn.1009-2501.2023.01.013

Previous Articles Next Articles

Research progress on the relationship between hypoglycemic drugs and sarcopenia

CAI Jing1,2, PAN Binjing1,2, LIU Jingfang2

1First College of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Endocrinology, First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China

Received:2022-05-17 Revised:2022-12-13 Online:2023-01-26 Published:2023-02-14

Abstract

Abstract: Sarcopenia is a disease characterized by a decrease in muscle mass and function that can induce adverse events such as falls, weakness, and death. The latest research shows that the use of many hypoglycemic drugs is associated with sarcopenia. Different types of hypoglycemic drugs may have different effects and mechanisms for the quality and function of skeletal muscle. In this paper, we review the research progress of the relationship between hypoglycemic drugs and sarcopenia and the molecular mechanism in recent years to provide a reference for the diagnosis and treatment prevention of sarcopenia in clinical areas.

Key words: sarcopenia, hypoglycemic drugs, type 2 diabetes

CLC Number:

R587.1

CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[4]	GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua. Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 341-346.
[5]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[6]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[7]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[8]	FU Yongfang, GUO Yixun, WANG Jing, LI Wenxiong, ZHANG Yan. Research progress on experimental pharmacology models of sarcopenia from the view of senescence [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 892-898.
[9]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[10]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[11]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[12]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[13]	CHEN Qian, WANG Yafeng, DUO Delong, CHANG Ya'e, YAN Yingjun, DUAN Kunkun. Trigliptin succinate have an effect on gut microbiota of type 2 diabetic mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 15-24.
[14]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[15]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.

Research progress on the relationship between hypoglycemic drugs and sarcopenia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments